Hemerion Therapeutics
PrivateLast Round
Series A
May 22, 2025
Est. Valuation
$32.94M
Total Funding Raised
$15.12M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Hemerion Therapeutics is a biotechnology company that develops therapeutic solutions combining photosensitizing molecules and laser light technologies to treat resistant tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hemerion Therapeutics Comparables
Compare Hemerion Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alpheus Medical | 79% | |
| ImPact Biotech | 76% | |
| Rakuten Medical | 76% |
Hemerion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 22, 2025 | ||||
| Grant | Apr 14, 2023 | ||||
| Seed | Apr 14, 2022 | ||||
| Seed | Jun 1, 2021 |
Key People
Founding team and executive leadership
Hemerion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Regional Development Fund | Series A |
| FIRA Nord-Est 2 | Series A |
| Finorpa | Series A, Seed |
| Siparex Group | Series A, Seed |
| Finovam Gestion | Series A, Seed |
| Bpifrance | Series A, Grant, Seed |
| Capital Cell | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 48% MoM.
- Aug 22, 2026
Monthly visitors grew 68% MoM, reaching 2.3K.
Hemerion Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Hemerion Therapeutics's valuation, stock price, and market status.
Is Hemerion Therapeutics a public or private company?
Hemerion Therapeutics is a private company.
What is the current stock price of Hemerion Therapeutics?
Hemerion Therapeutics is a private company, so its shares have no public market price. Caplight tracks Hemerion Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hemerion Therapeutics worth (valuation)?
Hemerion Therapeutics's valuation is estimated at $32.9M based on funding round data.
Can I buy Hemerion Therapeutics stock?
Hemerion Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hemerion Therapeutics's last funding round?
Hemerion Therapeutics's most recent funding round was Series A on May 22, 2025.
Who are the main investors in Hemerion Therapeutics?
Key investors in Hemerion Therapeutics include European Regional Development Fund, FIRA Nord-Est 2, Finorpa, Siparex Group, Finovam Gestion.
Will Hemerion Therapeutics IPO soon?
No public IPO plans have been announced for Hemerion Therapeutics.
How can I track Hemerion Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Hemerion Therapeutics's shares on secondary markets.